Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue: +2,356.5%
EPS: +46.3%
Free cash flow: −6.73%
Total debt: −83.9%

Quarter to September 2026, against a year earlier

54.93 0.62 −1.12%

Follow CYTK

Alert me

Market cap: $7.7B
P/E: 0.0×
Fwd P/E: −10.3×
Dividend yield: —
F-score: 2/9
Altman Z: −1.98
Beneish M: −0.44
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Cytokinetics, Incorporated (CYTK) revenue by segment, product and region

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2020	FY2019	FY2018	FY2017
License and Milestone Revenues	79 90.13%	15 81.20%	4 46.48%	1 1.06%	37 65.38%	0 0.00%	5 16.29%	9 65.82%
Collaboration Revenues	9 9.87%	3 18.80%	4 53.52%	7 6.96%	—	—	—	—
Realization of Revenue Participation Right Purchase Agreement	—	—	—	87 91.98%	0 0.00%	—	—	—
Research and Development Revenues	—	—	—	—	17 29.60%	27 100.00%	26 83.71%	5 34.18%
Milestone Revenues	—	—	—	—	3 5.02%	0 0.00%	0 0.00%	—
Revenue	88	18	8	95	56	27	32	13

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.

Cytokinetics, Incorporated (CYTK) revenue by segment, product and region

Revenue by product or service $m

Stockrow Weekly